We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Feasibility Study Supports Use of Immunomagnetic Approach to Study Circulating Cancer Cells

By LabMedica International staff writers
Posted on 01 Apr 2015
Cancer researchers have combined the strength of magnetic separation with the specificity of immunochemical biomarker recognition to demonstrate the feasibility of capturing and analyzing rare circulating cells from the blood stream of cancer patients.

Writing in the March 4, 2015, online edition of the journal Scientific Reports, investigators at Dartmouth College (NH, USA) described a two-dimensional micromagnet array that they used to characterize generation of the magnetic field and to quantify the impact of micromagnets on rare cell separation. More...
In this paper, they presented a theoretical framework and technical approach to implement microscale magnetic immunoassay through modulating the local magnetic field towards enhanced capture and distribution of rare cancer cells.

"The concept is to use novel cell-machine interfaces, integrated sensing, actuation, and biomarker recognition functionalities to isolate these rare cells (one per billion hematologic cells) from whole blood to determine malignancy unambiguously," said senior author Dr. John X.J Zhang, professor of engineering at Dartmouth College. "We will base the quantitative assessment on multiple tumor markers. This project demonstrates that a relatively simple blood test may eventually be able to provide unambiguous information to doctors about particular cancers in individuals."

The investigators found that there was good agreement between their theory and results of experiments using a human colon cancer cell line (COLO205) as the capture targets.

Related Links:

Dartmouth College



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.